News | September 04, 2008

Bypass Surgery Edges out DES for Treatment of Complex Heart Disease

September 5, 2008 - The results of the SYNTAX study, a head-to-head comparison between drug-eluting stents (DES) using percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in patients with complex coronary disease, showed bypass is a better option.

The results were announced Sept. 1 at the annual European Society of Cardiology meeting in Munich, Germany.

The overall 12-month adverse cardiovascular or cerebrovascular event rate, including all-cause death, stroke, MI and repeat revascularization, was significantly higher for PCI (17.8 percent compared to 12.1 percent for CABG). The 5.7 percent difference put CABG ahead of PCI as the winner in the study.

In other comparisons showed the safety rate for both techniques are comparable, with a combined rate of all-cause death, stroke and MI of 7.6 percent for PCI and 7.7 percent for CABG. The rate of stroke itself was 0.6 percent for PCI as compared to 2.2 percent for CABG, showing DES better at preventing strokes.

The SYNTAX trial was designed to compare CABG and PCI (using drug coated stents) in patients with coronary blockages affecting either the left main coronary artery (an artery which supplies the vast majority of heart muscle) and/or blockages in multiple other coronary arteries. The study enrolled 1,800 patients, who were split equally into two groups receiving the different treatments.

Patients undergoing PCI received an average number of 4.6 stents, and patients in the CABG group received an average number of 2.8 grafts.

While the results of the trial showed bypass is a little better than DES, Boston Scientific (the sponsor of the trial) said the SYNTAX trial showed comparable safety outcomes for complex patients treated with the TAXUS Express2 DES stents used in the study and bypass surgery. The company said the overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI).

The SYNTAX trial is the first randomized, controlled clinical trial to compare PCI using DES to CABG in patients with left main disease and three-vessel disease. These patient groups are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior DES clinical trials. The goal of the trial was to expand the body of knowledge of PCI use and help inform physicians on appropriate treatment options for the sickest patients.

The patients recruited in SYNTAX are a unique study group in the PCI field, given their exceptionally complex anatomy and advanced disease. The average SYNTAX patient received 4.6 stents, with one patient having 14. By contrast, the average number of stents implanted in a PCI patient in everyday practice is 1.5. In addition, the patient profile includes 33 percent of patients with >100 mm stented length, 84 percent with bi/trifurcations, 22 percent with chronic total occlusions, and 39 percent with left main disease. Some of the sickest patients in the trial were not eligible for surgery and were treated with drug-eluting stents.

For more information: www.bostonscientific.com

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init